Cancer Discov. 2014 Jul;4(7):752-3. doi: 10.1158/2159-8290.CD-NB2014-069. Epub 2014 May 8.
Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.
基于关键 III 期 REGARD 试验的数据，FDA 批准雷莫芦单抗作为晚期胃癌和胃食管交界处腺癌患者的二线治疗药物。
